3D MRE-Based Evaluation of Meningioma Mechanical Properties and Histological Features

Launched by SHENGJING HOSPITAL · Apr 24, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new imaging technique called three-dimensional magnetic resonance elastography (3D MRE) to understand the characteristics of meningiomas, which are tumors that grow on the membranes surrounding the brain and spinal cord. The goal is to see if this noninvasive method can help doctors assess how stiff the tumor is and how it is attached to surrounding tissues before surgery. By comparing these imaging results with what doctors find during surgery and through lab tests, the researchers hope to determine if 3D MRE can be a valuable tool for planning surgeries and predicting how the tumor might behave.

To participate in this study, patients must be scheduled for surgery to remove a meningioma. However, some individuals may not be eligible, including those with metal implants in their bodies (like pacemakers or artificial joints), pregnant women in their first trimester, or anyone with severe anxiety or claustrophobia that makes it hard for them to undergo an MRI scan. During the study, participants will undergo the 3D MRE test before their surgery, which is painless and does not involve any invasive procedures. This trial is currently recruiting participants and is open to both men and women aged 18 to 85 who meet the eligibility criteria.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • All patients undergoing meningeoma resection surgery are eligible for inclusion in the study cohort.
• Exclusion Criteria:
• • Patients with metallic implants or foreign bodies in their bodies (pacemakers, artificial metallic heart valves, metal joints, metal implants, and those who can not remove dentures, insulin pumps, or contraceptive rings)
• • Pregnant women in the first trimester (within three months)
• • Patients with severe claustrophobia or anxiety
• • Patients with severe fever
• • Patients who can not tolerate MRE
• • Patients with vascular malformations and aneurysms.
• • Patients who do not sign an informed consent